Pax5: a Master Regulator of B Cell Development and Leukemogenesis
Overview
Affiliations
The B cell lineage of the hematopoietic system is responsible for the generation of high-affinity antibodies, which provide humoral immunity for protection against foreign pathogens. B cell commitment and development depend on many transcription factors including Pax5. Here, we review the different functions of Pax5 in regulating various aspects of B lymphopoiesis. At B cell commitment, Pax5 restricts the developmental potential of lymphoid progenitors to the B cell pathway by repressing B-lineage-inappropriate genes, while it simultaneously promotes B cell development by activating B-lymphoid-specific genes. Pax5 thereby controls gene transcription by recruiting chromatin-remodeling, histone-modifying, and basal transcription factor complexes to its target genes. Moreover, Pax5 contributes to the diversity of the antibody repertoire by controlling V(H)-DJ(H) recombination by inducing contraction of the immunoglobulin heavy-chain locus in pro-B cells, which is likely mediated by PAIR elements in the 5' region of the V(H) gene cluster. Importantly, all mature B cell types depend on Pax5 for their differentiation and function. Pax5 thus controls the identity of B lymphocytes throughout B cell development. Consequently, conditional loss of Pax5 allows mature B cells from peripheral lymphoid organs to develop into functional T cells in the thymus via dedifferentiation to uncommitted progenitors in the bone marrow. Pax5 has also been implicated in human B cell malignancies because it can function as a haploinsufficient tumor suppressor or oncogenic translocation fusion protein in B cell precursor acute lymphoblastic leukemia.
Guo S, Cong B, Zhu L, Zhang Y, Yang Y, Qi X BMC Genomics. 2024; 25(1):1029.
PMID: 39497056 PMC: 11533344. DOI: 10.1186/s12864-024-10836-8.
Establishment of CD1b-restricted immunity to lipid antigens in the pulmonary response to infection.
Harris M, Gary H, Cooper S, Ackart D, DiLisio J, Basaraba R Infect Immun. 2024; 92(12):e0038024.
PMID: 39494875 PMC: 11629625. DOI: 10.1128/iai.00380-24.
Post-translational control of B lineage commitment.
Nie J, Ng A, Nutt S Nat Immunol. 2024; 25(12):2173-2175.
PMID: 39487350 DOI: 10.1038/s41590-024-02019-0.
Targeting DLBCL by mutation-specific disruption of cancer-driving oncogenes.
Heshmatpour N, Kazemi S, Schmidt N, Patnaik S, Korus P, Wilkens B Front Genome Ed. 2024; 6:1427322.
PMID: 39469218 PMC: 11513324. DOI: 10.3389/fgeed.2024.1427322.
Gamez-Garcia A, Espinosa-Alcantud M, Bueno-Costa A, Alari-Pahissa E, Marazuela-Duque A, Thackray J Nat Immunol. 2024; 25(12):2308-2319.
PMID: 39424985 PMC: 11588656. DOI: 10.1038/s41590-024-01995-7.